Low Lymphocyte Proportion in Bronchoalveolar Lavage Fluid as a Risk Factor Associated with the Change from Trimethoprim/sulfamethoxazole used as First-Line Treatment for Pneumocystis jirovecii Pneumonia

키워드

참고문헌 (28)

1. Catherinot E, "Pneumocystis jirovecii pneumonia", Infect Dis Clin North Am, 24, pp.107~138 (2010)[DOI]
2. Fillatre P, "Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients", Am J Med, 127, pp.1242.e11~1242.e17 (2014)[DOI]
3. Smego RA Jr, "A meta-analysis of salvage therapy for pneumocystis carinii pneumonia", Arch Intern Med, 161, pp.1529~1533 (2001)[DOI]
4. Kim T, "Outcomes of non-HIV-infected patients with Pneumocystis pneumonia and concomitant pulmonary cytomegalovirus infection", Scand J Infect Dis, 44, pp.670~677 (2012)[DOI]
5. Roblot F, "Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients", Eur J Clin Microbiol Infect Dis, 21, pp.523~531 (2002)[DOI]
6. Allegra CJ, "Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome", N Engl J Med, 317, pp.978~985 (1987)[DOI]
7. Walzer PD, "Priniciples and practice of infectious diseases", pp.3016~3030 (2015), Elsevier
8. Deresinski SC, "Caspofungin", Clin Infect Dis, 36, pp.1445~1457 (2003)[DOI]
9. Kim T, "Is caspofungin really an effective treatment for Pneumocystis jirovecii pneumonia in immunocompromised patients without human immunodeficiency virus infection? Experiences at a single center and a literature review", Scand J Infect Dis, 45, pp.484~488 (2013)[DOI]
10. Mitsides N, "Complications and outcomes of trimethoprim-sulphamethoxazole as chemoprophylaxis for pneumocystis pneumonia in renal transplant recipients", Nephrology (Carlton), 19, pp.157~163 (2014)[DOI]
11. Kim T, "Clindamycin-primaquine versus pentamidine for the second-line treatment of pneumocystis pneumonia", J Infect Chemother, 15, pp.343~346 (2009)[DOI]
12. Choi SH, "Viral infection in patients with severe pneumonia requiring intensive care unit admission", Am J Respir Crit Care Med, 186, pp.325~332 (2012)[DOI]
13. Horan TC, "CDC", NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting, 2008, pp.36, 309~332
14. Lee JY, "Cellular profiles of bronchoalveolar lavage fluid and their prognostic significance for non-HIV-infected patients with Pneumocystis jirovecii pneumonia", J Clin Microbiol, 53, pp.1310~1316 (2015)[DOI]
15. Fauchier T, "Detection of Pneumocystis jirovecii by quantitative PCR to differentiate colonization and pneumonia in immunocompromised HIV-positive and HIV-negative patients", J Clin Microbiol, 54, pp.1487~1495 (2016)[DOI]
16. Pfaller MA, "Clinical Mycology", pp.385~401 (2009), Churchill Livingstone
17. Moon SM, "Outcomes of moderate-to-severe Pneumocystis pneumonia treated with adjunctive steroid in non-HIV-infected patients", Antimicrob Agents Chemother, 55, pp.4613~4618 (2011)[DOI]
18. Edwards IR, "Adverse drug reactions: definitions, diagnosis, and management", Lancet, 356, pp.1255~1259 (2000)[DOI]
19. Jensen BN, "Cellular profiles in bronchoalveolar lavage fluid of HIV-infected patients with pulmonary symptoms: relation to diagnosis and prognosis", AIDS, 5, pp.527~533 (1991)[DOI]
20. Benfield TL, "Neutrophil chemotactic activity in bronchoalveolar lavage fluid of patients with aids-associated Pneumocystis carinii pneumonia", Scand J Infect Dis, 29, pp.367~371 (1997)[DOI]
21. Duong T, "Laboratory and clinical predictors of disease progression following initiation of combination therapy in hiv-infected adults in Thailand", PLoS One, 7, pp.e43375~ (2012)[DOI]
22. Struijk GH, "Risk of Pneumocystis jiroveci pneumonia in patients long after renal transplantation", Nephrol Dial Transplant, 26, pp.3391~3398 (2011)[DOI]
23. Hashimoto K, "Pneumocystis jiroveci pneumonia in relation to cd4+ lymphocyte count in patients with b-cell non-hodgkin lymphoma treated with chemotherapy", Leuk Lymphoma, 51, pp.1816~1821 (2010)[DOI]
24. Fei MW, "Predicting mortality from HIV-associated Pneumocystis pneumonia at illness presentation: an observational cohort study", Thorax, 64, pp.1070~1076 (2009)[DOI]
25. Shahrin L, "Characteristics and predictors of death among hospitalized HIV-infected patients in a low HIV prevalence country: Bangladesh", PLoS One, 9, pp.e113095~ (2014)[DOI]
26. Ruf B, "Efficacy of clindamycin", primaquine versus trimethoprim, Eur J Clin Microbiol Infect Dis, pp.1991, 10[DOI]
27. Toma E, "Clindamycin with primaquine vs. Trimethoprim-sulfamethoxazole therapy for mild and moderately severe pneumocystis carinii pneumonia in patients with aids: A multicenter, double-blind, randomized trial (CTN 004). CTN-PCP study group", Clin Infect Dis, 27, pp.524~530 (1998)[DOI]
28. Helweg-Larsen J, "Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study", J Antimicrob Chemother, 64, pp.1282~1290 (2009)[DOI]

관련 논문AI추천